Nanobiotix (NBTX) announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating radioenhancer JNJ-1900 for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab. CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson (JNJ) company, under a global license agreement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix Updates Voting Rights and Share Capital Information
- Nanobiotix to Unveil Future of Nanotherapeutics
- Nanobiotix Announces Key Share Acquisition Transactions
- Nanobiotix Executive Acquires Significant Share Volume, Signaling Confidence in Future Growth
- Nanobiotix Updates Share Capital and Voting Rights Information